Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCICn         CTG CO.17: a phase III trial of cetuximab versus best supportive care

C. J. OCallaghan

首页> 外文期刊>Annals of Oncology >Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCICn CTG CO.17: a phase III trial of cetuximab versus best supportive care

【24h】

Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCICn CTG CO.17: a phase III trial of cetuximab versus best supportive care

机译：西妥昔单抗治疗的晚期大肠癌（ACRC）患者的合并症，年龄和总生存率-NCICn CTG CO.17的结果：西妥昔单抗与最佳支持治疗的III期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The interplay between comorbidity, age and performance status (PS) as predictors of outcome in advanced colorectal cancer (ACRC) is poorly understood. We examined these factors as predictors of treatment toxicity and outcome in cetuximab-treated patients with ACRC.

机译：背景：合并症，年龄和表现状态（PS）之间的相互作用作为晚期结直肠癌（ACRC）结局的预测因子了解甚少。我们检查了这些因素作为西妥昔单抗治疗的ACRC患者治疗毒性和预后的指标。

著录项

来源
《Annals of Oncology》 |2011年第1期|p.118-126|共9页
作者
C. J. OCallaghan;
展开▼
作者单位

Dr T. R. Asmis, Department of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6. Tel: +1-613-737-8899;

Fax: +1-613-247-3511;

E-mail:;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. [J] . Asmis TR, Powell E, Karapetis CS, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第1期

机译：西妥昔单抗治疗的晚期大肠癌（ACRC）患者的合并症，年龄和总生存率-NCIC CTG CO.17的结果：西妥昔单抗与最佳支持治疗的III期试验。
2. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17 [J] . VickersM.M., KarapetisC.S., TuD., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第4期

机译：低镁血症与III期生存率低下的关联，西妥昔单抗联合最佳支持治疗与仅最佳支持治疗的随机研究：NCIC CTG / AGITG CO.17
3. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment [J] . Van Cutsem Eric, Yoshino Takayuki, Hocke Julia, Clinical colorectal cancer . 2016,第1期

机译：LUME-Colon 1研究的基本原理和设计：Nintedanib加最佳支持治疗的随机，双盲，安慰剂对照的III期临床试验与安慰剂加最佳支持治疗的难治性标准治疗大肠癌患者
4. Stage III endobronchial squamous cell cancer: survival after Nd:YAG laser combined with photodynamic therapy versus Nd:YAG laser or photodynamic therapy alone [C] . James S. McCaughan, Jr., Laser Medical Research Foundation, Optical Methods for Tumor Treatment and Early Diagnosis: Mechanisms and Techniques . 1991

机译：III期支气管内鳞状细胞癌：Nd：YAG激光联合光动力治疗与单独Nd：YAG激光或光动力治疗相比生存率
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Treatment rationale and study design for a phase III double-blind placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer [O] . Luis G Paz-Ares, Sedat Altug, Alexandra Thareau Vaury, 2010

机译：培美曲塞加顺铂治疗晚期非鳞状非小细胞肺癌后立即进行培美曲塞加最佳支持治疗与最佳支持治疗的III期双盲安慰剂对照研究的治疗原理和研究设计
7. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial [O] . Au, Heather-Jane, Karapetis, Christos S., Ou27Callaghan, Chris J., 2009

机译：西妥昔单抗治疗的晚期大肠癌患者的健康相关生活质量：NCIC CTG和AGITG CO.17的总体和KRAS特异性结果

Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCICn CTG CO.17: a phase III trial of cetuximab versus best supportive care

摘要

著录项

相似文献

相关主题

期刊订阅